Molecular imaging developer Sofie Biosciences has been told that it will receive a U.S. patent that covers a line of novel PET probes, known as F-18 FAC.
Basic and clinical scientists at the University of California, Los Angeles invented the class of PET probes, which measure an enzyme, dCK, that controls the rate of DNA production through the salvage pathway. Tumors use the pathway to provide high rates of DNA replication for the uncontrolled growth of malignant cells.
Sofie said it has obtained an exclusive license for F-18 FAC. Three investigational new drug applications have been approved for F-18 FAC and two analogs, and clinical trials have been initiated.
